Comparison of effects of tamoxifen and toremifene on bone biochemistry and bone mineral density in postmenopausal breast cancer patients

Journal of Clinical Endocrinology and Metabolism

Volumn 83, Issue 4, 1998, Pages 1158-1162

  Marttunen, Merja B ^a   Hietanen, Päivi ^a   Tiitinen, Aila ^a   Ylikorkala, Olavi ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; ANTIESTROGEN; BIOCHEMICAL MARKER; COLLAGEN TYPE 1; HYDROXYPROLINE; OSTEOCALCIN; PROCOLLAGEN; TAMOXIFEN; TOREMIFENE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FEMUR; HUMAN; LUMBAR SPINE; MULTICENTER STUDY; OSSIFICATION; OSTEOLYSIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031764190     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.83.4.4688     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group. 1992 Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet. 339:1-15:71-85.
2. Powles TJ. 1992 The case for clinical trials of tamoxifen for prevention of breast cancer. Lancet. 340:1145-1147.
3. Jordan VC. 1995 Alternate antiestrogens and approaches to the prevention of breast cancer. J Cell Biochem. 22:51-57.
4. Coezy E, Borgna JL, Rochefort H. 1982 Tamoxifen and metabolites in MCF-7 cells: correlation between binding to estrogen receptor and inhibition of cell growth. Cancer Res. 42:317-323.
5. Colletta AA, Benson JR, Baum M. 1994 Alternative mechanisms of action of anti-oestrogens. Breast Cancer Res Treat. 31:5-9.
6. Bagdade JD, Wolter J, Subbaiah PV, Ryan W. 1990 Effects of tamoxifen on plasma lipids and lipoprotein lipid composition. J Clin Endocrinol Metab. 70:1132-1135.
7. Neven P, Shepherd JH, Lowe DG. 1993 Tamoxifen and gynaecologist. Br J Obstet Gynecol. 100:893-897.
8. Love RR, Mazess RB, Barden HS, et al. 1992 Effects of tamoxifen on bone mineral density in post-menopausal women with breast cancer. N Engl J Med. 326:852-856.
9. Ward RL, Morgan G, Dalley D, Kelly PJ. 1993 Tamoxifen reduces bone turnover and prevents lumbar spine and proximal femoral bone loss in early postmenopausal women. Bone Miner. 22:87-94.
10. Grey AB, Stapleton JP, Evans MC, Tatnell MA, Ames RW, Reid IR. 1995 The effect of the antiestrogen tamoxifen on bone mineral density in normal late postmenopausal women. Am J Med. 99:636-641.
11. Powles TJ, Hickish T, Kanis JA, Tidy A, Ashley S. 1996 Effect of tamoxifen on bone mineral density measured by dual-energy X-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol. 14:78-84.
12. Kangas L. 1990 Introduction to toremifene. Breast Cancer Res Treat. [Suppl] 16:3-7.
13. Stenbygaard LE, Herrstedt J, Thomsen JF, Svendsen KR, Engelholm SA, Dombernowsky P. 1993 Toremifene and tamoxifen in advanced breast cancer - a double-blind crossover trial. Breast Cancer Res Treat. 25:57-63.
14. Hayes DF, Van Zyl JA, Hacking A, et al. 1995 Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol. 13:2556-2566.
15. Howell A, Downey S, Anderson E. 1996 New endocrine therapies for breast cancer. Eur J Cancer 32:A576-A588.
16. Gylling H, Pyrhönen S, Mäntylä E, Mäenpää H, Kangas L, Miettinen T. 1995 Tamoxifen and toremifene lower serum cholesterol by inhibition of delta 8-cholesterol conversion to lathosterol in women with breast cancer. J Clin Oncol. 13:2900-2905.
17. Saarto T, Blomqvist C, Ehnholm C, Taskinen MR, Elomaa I. 1995 Antiatherogenic effects of adjuvant antiestrogens; a randomized trial comparing the effects of tamoxifen and toremifene on plasma lipid levels in postmenopausal women with node-positive breast cancer. J Clin Oncol. 14:429-433.
18. Tomas E, Kauppila A, Blanco G, Apaja-Sarkkinen M, Laatikainen T. 1995 Comparison between the effects of tamoxifen and toremifene on the uterus in postmenopausal breast cancer patients. Gynecol Oncol. 59:261-266.
19. Turpeinen U, Pomoell UM. 1985 Liquid-chromatographic determination of total hydroxyproline in urine. Clin Chem. 31:828-830.
20. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Eyre DR. 1992 A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res. 7:1251-1258.
21. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. 1993 Radioimmunoassay for the pyridinoline cross-linked carboxyterminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem. 39:635-640.
22. Epstein S. 1988 Serum and urinary markers of bone remodelling: assessment of bone turnover. Endocr Rev. 9:437-449.
23. Melkko J, Kauppila S, Niemi S, et al. 1996 Immunoassay for intact aminoterminal propeptide of human type I procollagen. Clin Chem. 42:947-954.
24. De Boer H, Blok GJ, Van Lingen A, Teule GJJ, Lips P, Van Der Veen EA. 1994 Consequences of childhood-onset growth hormone deficiency for adult bone mass. J Bone Miner Res. 9:1319-1326.
25. Jaiyesimi IA, Buzdar AU, Decker DA, Hortobagyi GN. 1995 Use of tamoxifen for breast cancer: twenty-eight years later. J Clin Oncol. 13:513-529.
26. Turner RT, Riggs BL, Spelsberg TC. 1994 Skeletal effects of estrogen. Endocr Rev. 15:275-300.
27. Christiansen C. 1996 Hormone replacement therapy and osteoporosis. Maturitas. [Suppl] 23:71-76.
28. Calvo MS, Eyre DR, Gundberg CM. 1996 Molecular basis and clinical application of biological markers of bone turnover. Endocr Rev. 17:333-368.
29. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD. 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab. 79:1693-1700.
30. Kangas L. 1992 Agonistic and antagonistic effects of antiestrogens in different target organs. Acta Oncol. 31:143-146.
31. Prince RL, Smith M, Dick IM, et al. 1991 Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation and hormone-replacement therapy. N Engl J Med. 325:1189-1195.
32. Hansen MA, Overgaard K, Riis BJ, Christiansen C. 1991 Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ. 303:961-964.
33. Lindsay R. 1996 The oestrogen receptor in bone - evolution of our knowledge. Br J Obstet Gynecol. 103:16-19.